15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $67M | -$279M | 0.0% | -449.9% | -160.0% | -37.7% | -$71M | $10M | $149M |
| 2024 | $54M | -$174M | 0.0% | -358.5% | -42.1% | -22.9% | $134M | $10M | $224M |
| 2023 | $0 | -$153M | — | — | -38.4% | -34.0% | -$125M | $9M | $37M |
| 2022 | — | -$136M | — | — | -32.3% | -29.8% | -$111M | $9M | $52M |
| 2021 | — | -$130M | — | — | -25.8% | -24.4% | -$106M | — | $91M |
| 2020 | — | -$90M | — | — | -14.7% | -13.8% | -$72M | $7M | $325M |
| 2019 | — | -$63M | — | — | -28.9% | -26.1% | — | $8M | $26M |
| 2018 | — | -$60M | — | — | -37.5% | -33.1% | — | $8M | $16M |
| 2017 | — | -$35M | — | — | -44.4% | -37.0% | — | $7M | $11M |
| 2016 | — | -$28M | — | — | -48.5% | -39.5% | — | $7M | $10M |
| 2015 | — | -$23M | — | — | -27.6% | -25.9% | — | — | $15M |
| 2014 | — | -$30734 | — | — | 0.9% | -2.2% | — | — | $1M |
| 2014 | — | -$193038 | — | — | 135.0% | -1059.7% | — | — | $82000 |
| 2014 | — | -$186610 | — | — | 136.6% | -3794.4% | — | — | $4918 |
| 2014 | — | -$179723 | — | — | 138.5% | -2645.7% | — | — | $6168 |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $21M | -$68M | 98.8% | -349.8% | -141.1% | -11.6% | -$63M | $10M | $70M |
| Mar '26 | $18M | -$73M | 98.6% | -431.5% | -68.0% | -11.2% | -$86M | $10M | $39M |
| Dec '25 | $17M | -$81M | 0.0% | -497.6% | -46.5% | -11.0% | $115M | $10M | $149M |
| Sep '25 | $21M | -$74M | 0.0% | -385.5% | -30.6% | -11.4% | -$83M | $10M | $95M |
| Jun '25 | $15M | -$66M | 0.0% | -475.3% | -21.6% | -9.7% | -$30M | $10M | $82M |
| Mar '25 | $14M | -$57M | 0.0% | -458.6% | -15.8% | -7.7% | -$72M | $10M | $51M |
| Dec '24 | — | -$19M | — | — | -4.6% | -2.5% | $269M | $10M | $224M |
| Sep '24 | — | -$54M | — | — | -12.8% | -11.4% | -$43M | $9M | $49M |
| Jun '24 | — | -$51M | — | — | -10.9% | -9.9% | -$43M | $9M | $45M |
| Mar '24 | — | -$50M | — | — | -9.8% | -8.9% | -$49M | $9M | $42M |
| Dec '23 | — | -$43M | — | — | -10.8% | -9.5% | -$34M | $9M | $37M |
| Sep '23 | — | -$39M | — | — | -9.0% | -8.1% | -$29M | $9M | $29M |
| Jun '23 | — | -$37M | — | — | -8.1% | -7.5% | -$26M | $9M | $49M |
| Mar '23 | — | -$34M | — | — | -8.6% | -8.0% | -$36M | $9M | $27M |
| Dec '22 | — | -$33M | — | — | -7.9% | -7.3% | -$27M | $9M | $52M |
| Sep '22 | — | -$36M | — | — | -8.5% | -7.9% | -$21M | — | $91M |
| Jun '22 | — | -$35M | — | — | -7.7% | -7.4% | -$31M | — | $39M |
| Mar '22 | — | -$32M | — | — | -6.8% | -6.5% | -$32M | — | $34M |
| Dec '21 | — | -$33M | — | — | -6.5% | -6.1% | -$23M | — | $91M |
| Sep '21 | — | -$33M | — | — | -6.3% | -5.9% | -$25M | — | $39M |
How the market has priced KURA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
See the revenue and net-income charts above for Kura Oncology, Inc.'s multi-year trend.
As of FY2025, Kura Oncology, Inc. reported $10M of total debt against $149M of cash; operating income covered interest expense -200.8×.
In FY2025, gross margin was —, operating margin -449.9%, and net margin -412.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.